Arrieta O, Aviles-Salas A, Orozco-Morales M, et al. - In tumor biopsies from 169 Non-Small Cell Lung Cancer (NSCLC) patients, researchers immunohistochemically assessed CD47 (cluster of differentiation 47) expression (an antiphagocytic molecule that adds to tumor cell resistance in host immune surveillance) in this retrospective analysis. They assessed the link of CD47 levels (H-score) with clinicopathological features as well as survival results. They identified CD47 protein in 84% of patients with a median expression of 80% (0-100). In NSCLC patients, CD47 overexpression did not serve as a prognostic factor for progression-free survival (PFS) and overall survival (OS). However, shortened PFS and OS were evident in relation to the presence of EGFR mutations and high expression of CD47. The coexpression of these markers serves as a potential biomarker and describes a therapeutic niche for lung cancer.